Proprietary drug names meeting
This article was originally published in The Tan Sheet
Public meeting on "Minimizing Medication Errors - Methods for Evaluating Proprietary Names for Their Confusion Potential" will be held June 26 by FDA, PhRMA, Institute for Safe Medication Practices (ISMP), according to 1May 30 Federal Register notice. Goal of meeting is to solicit views on FDA recommendation that drug manufacturers "perform proprietary name testing prior to submitting NDAs and ANDAs," agency says. Input from workshop, other comments "may be considered in developing a draft guidance on this topic," FDA adds...
You may also be interested in...
CBER Director Peter Marks said the agency could streamline development by allowing sponsors to depend on an already-approved manufacturing platform and reviewing any modifications that are proposed.
Only 12 US jurisdictions currently have sound COVID-19 virus assays from the Centers for Disease Control and Prevention to test suspected virus cases, CDC director Robert Redfield told a House panel looking at virus preparedness on Wednesday – but a better batch is coming, he said. Other questions raised at the congressional hearing was how long an infected person stays infected, whether COVID-19 can be picked up from inanimate surfaces, and related queries.
Personal-care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3 – Cosmetics and Cleaning Preps.